Human F7 ELISA Kit

Major Depressive Disorder is one of the principal causes of disability globally. It is characterized by low self-regard and thoughts of hopelessness. This study aims at analyzing the brain activity during emotional processing in depressed patients. Fifteen adults with a HDRS-17 score of greater than 20 participated in the study. EEG was recorded while viewing two categories of IAPS pictures namely, neutral and high valence high arousal. SAM scale was utilized to find the perceptual emotions of the participants. The behavioral study showed a neutral response for both the sets of pictures. The mean relative power of alpha was observed to be elevated in left frontal region indicating negative emotion. Significant changes in mean relative beta power was observed between high valence high arousal stimuli (F3=0.01, F4=0.016, F7=0.013, F8=0.007) and neutral stimuli (F3=0.004, F4=0.005, F7=0.002, F8=0.002), indicating arousal though it is not perceived. Frontal alpha asymmetry scores, with the significance of p<0.05, showed withdrawal behavior while viewing the pictures when compared to rest. It is concluded that negative emotion for both neutral and positive stimuli could be a characteristic feature for Major Depressive Disorder.

Gastroesophageal reflux disease (GERD) is an esophageal injury occurred when the stomach contents reflux abnormally into the esophagus. GERD complications include esophageal adenocarcinoma. Mosapride (MOS) is a safe prokinetic agent potentially used to treat GERD. Yet, its low solubility and bioavailability due to extensive first-pass metabolism limits its applications. This study aimed to formulate MOS nanostructured lipid carriers (MOS-NLCs) via the intranasal route to improve its bioavailability. Melt-emulsification low temperature-solidification technique using 2(3) full factorial design was adopted to formulate MOS-NLCs. Eight formulae were prepared and assessed in terms of entrapment efficiency (%EE), particle size, and in vitro release. Glycerol addition significantly reduced the particle sizes and improved %EE and %drug released. Surface modification using chitosan was applied. The optimized MOS surface-modified nanostructured lipid carriers (MOS-SMNLCs-F7)(stearic acid, 4% glycerol, 0.5% LuterolF127, 0.5% chitosan) showed low particle size 413.8nm +/- 11.46nm and high %EE 90.19%+/- 0.06% and a threefold increase in permeation of MOS with respect to the drug suspension. MOS-SMNLCs (F7) was also evaluated for its bioavailability compared with drug suspension and commercial product. Statistical analysis revealed a significant increase in gastric emptying rate to be 21.54 +/- 1.88 contractions/min compared with10.02 +/- 0.62 contractions/min and 8.9 +/- 0.72 contractions/min for drug suspension and oral marketed product respectively. Pharmacokinetic studies showed 2.44-fold rise in bioavailability as compared to MOS suspension and 4.54-fold as compared to the oral marketed product. In vitro/in vivo studies proven to level A correlation between in vitro permeation through sheep nasal mucosa and in vivo absorption. Therefore, MOS-SMNLCs could be considered a step forward towards enhancing the clinical efficacy of Mosapride.